Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology, Inc. | LinkedIn
Articles about Puma Biotechnology | page 6
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology - Crunchbase Company Profile & Funding
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Inc
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Alan H. Auerbach - Founder, Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
SEC charges former Puma biotech exec with $1.1 million in insider trading
